These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B. J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [Abstract] [Full Text] [Related]
13. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X. J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469 [Abstract] [Full Text] [Related]
14. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Mol Imaging Biol; 2003 Jul; 5(1):42-8. PubMed ID: 14499161 [Abstract] [Full Text] [Related]
15. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ. Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915 [Abstract] [Full Text] [Related]
18. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218 [Abstract] [Full Text] [Related]
19. Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT. Cheng C, Heiss C, Dimitrakopoulou-Strauss A, Govindarajan P, Schlewitz G, Pan L, Schnettler R, Weber K, Strauss LG. Am J Nucl Med Mol Imaging; 2013 Apr; 3(2):118-28. PubMed ID: 23526138 [Abstract] [Full Text] [Related]
20. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Liu Z, Yan Y, Liu S, Wang F, Chen X. Bioconjug Chem; 2009 May 20; 20(5):1016-25. PubMed ID: 20540537 [Abstract] [Full Text] [Related] Page: [Next] [New Search]